Last reviewed · How we verify

NCT05601258

Lipase Levels and Coronavirus Disease 2019

Completed Last updated 1 November 2022
What this trial tests

trial testing Age, gender, hospitalization and mortality rates will be compared in Pancreatitis in 4,000 participants. Completed in 9 July 2021.

Timeline
31 March 2020
Primary endpoint
9 July 2021
9 July 2021

Quick facts

Lead sponsorUşak University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment4,000
Start date31 March 2020
Primary completion9 July 2021
Estimated completion9 July 2021
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Uşak University

Who can join

Eligibility, any sex, with Pancreatitis or Lipase Increased. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Although COVID-19 disease due to Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) affects the respiratory tract, heart and coagulation system, symptoms of gastrointestinal system involvement such as abdominal pain, nausea, vomiting and diarrhea are also common. In this study, it was aimed retrospective analysis of clinical and laboratory data of patients who developed pancreatic injury and acute pancreatitis in the course of COVID 19 disease.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Pancreatitis

Currently open trials in the same condition.

Other Uşak University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05601258.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing